Frequently Asked Questions
Health and safety are our top priorities in clinical research studies. Institutional Review Boards and Ethics Committees (independent groups of experts) must completely review a clinical research study before it begins. These groups make sure that:
- The rights and privacy of study participants are protected.
- Strict safety measures are in place throughout the entire study.
- The clinical research study follows the standards and regulations of the country it is taking place in.
The study doctor and study team will discuss the eligibility requirements with you to see if you qualify for this study. You can start the process by answering a few questions in this study website’s pre-screener questionnaire. Answering these questions does not mean that you have to participate in this clinical research study.
Participating in a clinical research study is 100% voluntary. You can choose to stop participating at any point, for any reason. Your choice to stop the study will have no impact on the medical care you receive outside of the study.
The investigational study drug is given as an infusion through the vein. You will receive an infusion of the investigational study drug once every 3 or 4 weeks, depending on the schedule decided by your study doctor.
You may have discomforts and risks from the investigational study drug and study procedures. These may vary from person to person. Everyone taking part in the study will be watched carefully for side effects; however, doctors do not know all the discomforts and risks that may happen. Please talk to the study doctor for more information.
Please consult with the study doctor and study team about the medications, supplements, and vitamins you are currently taking. There are certain medications, supplements, vitamins, and vaccines that you will not be able to take during this clinical research study. The study doctor and study team will review this with you.
There will be about 183 people participating globally.
Absolutely, you should continue to visit your other healthcare providers for care that is not a part of the MMyrelis clinical research study. We encourage all our participants to share information about this study to their treating physicians and decide together if this study can be part of their treatment plan. Below is a link to our Healthcare Professional Flyer, please feel free to print or email it to your treating physician and/or care staff.
Study-related procedures and drugs will be provided to the participant at no costs. This may include study-related travel expenses based on regional regulatory approvals. Please discuss with the study doctor and team.
If this study isn’t the right fit for you, but you’d like to stay informed about future Takeda studies that may align better with your needs, we encourage you to visit WeConnect. There, you can explore our current studies, and if none seem suitable, you can share your information with us to stay updated on future opportunities that might be a better match.
English